This article is more than 5 years old. Information may no longer be current.

VIDEO: Eisai executive highlights thyroid cancer data, company pipeline

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Kirk Shepard, MD, senior vice president, chief medical officer and head of global medical affairs for the oncology business group at Eisai, spoke with HemOnc Today at ASCO Annual Meeting about key data the company presented at the conference.

Shepard highlighted data from the SELECT trial related to the timing of treatment initiation with lenvatinib (Lenvima) for patients with advanced thyroid cancer.

“We know Lenvima is very effective as far as response rate ... but should we start it now or wait until later?” Shepard said. “These data tell us we should go ahead and start early.”

Shepard spoke about the potential of lenvatinib in combination with other immuno-oncology agents.

He also provided insights into other agents in Eisai’s pipeline. – by Mark Leiser